1. Signaling Pathways
  2. Immunology/Inflammation
  3. Toll-like Receptor (TLR)
  4. TLR8 Isoform

TLR8

 

TLR8 Related Products (24):

Cat. No. Product Name Effect Purity
  • HY-13740
    Resiquimod
    Agonist 99.95%
    Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.
  • HY-109104
    Telratolimod
    Agonist 99.04%
    Telratolimod (MEDI9197) is a potent toll like receptors 7/8 (TLR7/8) agonist, with antitumor activity.
  • HY-134581
    Enpatoran
    Inhibitor 99.77%
    Enpatoran (M5049) is a potent, orally active and dual TLR7/8 inhibitor with IC50s of 11.1 nM and 24.1 nM in HEK293 cells, respectively.
  • HY-134581A
    Enpatoran hydrochloride
    Inhibitor 98.82%
    Enpatoran (M5049) hydrochloride is a potent, orally active and dual TLR7/8 inhibitor with IC50s of 11.1 nM and 24.1 nM in HEK293 cells, respectively.
  • HY-109137
    Selgantolimod
    Agonist 99.17%
    Selgantolimod (GS-9688) is an orally active, potent and selective toll-like receptor 8 (TLR8) agonist for the treatment of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infection.
  • HY-145960
    MC-Val-Cit-PAB-Amide-TLR7 agonist 4
    Agonist 99.39%
    MC-Val-Cit-PAB-Amide-TLR7 agonist 4 (example 15) is a HER2-TLR7 and HER2-TLR8 immune agonist conjugate.
  • HY-128799A
    CL097 hydrochloride
    Agonist 99.51%
    CL097, a potent TLR7 and TLR8 agonist, induces pro-inflammatory cytokines in macrophages.
  • HY-112667
    CU-CPT-9a
    Antagonist 99.36%
    CU-CPT-9a is a specific TLR8 antagonist, with an IC50 of 0.5 nM.
  • HY-103697A
    Gardiquimod diTFA
    Agonist 99.77%
    Gardiquimod diTFA, an imidazoquinoline analog, is a TLR7/8 agonist.
  • HY-112050
    CU-CPT-8m
    Antagonist 99.98%
    CU-CPT-8m is a specific TLR8 antagonist, with an IC50 of 67 nM.
  • HY-101929
    CU-CPT17e
    Agonist ≥98.0%
    CU-CPT17e is a potent multi-Toll-like receptor (TLR) agonist that activates TLR3, TLR8, and TLR9.
  • HY-117066
    CL075
    Agonist 99.25%
    CL075 (3M002) is a selective TLR8 agonist with immunomodulating properties.
  • HY-130797
    TLR7/8 agonist 3
    Agonist 99.02%
    TLR7/8 agonist 3 is a potent TLR7 and TLR8 agonist, extracted from patent WO2016057618 (compound of formula (II)).
  • HY-139323
    TLR7/8-IN-1
    Inhibitor 99.80%
    TLR7/8-IN-1 is a crystalline from of a TLR7/TLR8 inhibitor extracted from patent WO2019220390, compound 2b.
  • HY-131945
    CU-115
    Antagonist 98.10%
    CU-115 is a potent TLR8 antagonist (IC50=1.04 µM), and shows selective for TLR8 over TLR7 (IC50=>50 µM).
  • HY-112051
    CU-CPT9b
    Antagonist 99.03%
    CU-CPT9b is a specific TLR8 antagonist, with an IC50 of 0.7 nM.
  • HY-128799
    CL097
    Agonist 99.89%
    CL097, a potent TLR7 and TLR8 agonist, induces pro-inflammatory cytokines in macrophages.
  • HY-138139A
    AXC-715 hydrochloride
    Agonist
    AXC-715 (T785) hydrochloride is a TLR7/TLR8 dual agonist, extracted from patent WO2020168017 A1.
  • HY-139017
    TLR7/8 agonist 4
    Agonist
    TLR7/8 agonist 4 (compound 41) is a potent TLR7/8 agonist.
  • HY-141454A
    TLR8 agonist 2 hydrochloride
    Agonist
    TLR8 agonist 2 hydrochloride is a potent and selective TLR8 agonist with an EC50 of 3 nM for human TLR8.